Physician profile
Murray Brand
NPI 1124061221
$3,893.23
in general payments reported to CMS, 2019-2025
35 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,568 · 2020: $721 · 2023: $85.06 · 2024: $263 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $616.39 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $613.58 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $294.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.74 | 2019-2020 | |
| Pfizer INC. | $254.37 | 2019-2025 | |
| Daiichi Sankyo INC. | $209.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.33 | 2019 | |
| Amgen INC. | $183.88 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $164.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $134.29 | 2019 | |
| Merck Sharp & Dohme LLC | $127.13 | 2019-2020 | |
| Abbvie INC. | $75.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $67.00 | 2019-2020 | |
| Sanofi Pasteur INC. | $63.58 | 2019-2020 | |
| Astellas Pharma US INC | $50.52 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $47.34 | 2019 | |
| Gilead Sciences, INC. | $47.11 | 2019-2023 | |
| Kvk-Tech, INC. | $44.55 | 2025 | |
| Indivior INC. | $41.08 | 2019-2025 | Sublocade |
| Kowa Pharmaceuticals America, INC. | $40.15 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $35.11 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $30.02 | 2024 | Pyrukynd |
| Teva Pharmaceuticals USA, INC. | $29.15 | 2019-2020 | |
| Allergan, INC. | $28.53 | 2019 | |
| Lilly USA, LLC | $26.33 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $26.10 | 2024 | Gemtesa |
| Aimmune Therapeutics, INC. | $25.67 | 2025 | Zenpep |
| Abbott Laboratories | $24.22 | 2024 | Freestyle Libre 3 |
| Shire North American Group INC | $17.48 | 2019 | |
| Mylan Specialty L.P. | $16.89 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.18 | 2025 | Nuzyra |
| Scilex Pharmaceuticals INC. | $15.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.29 | 2024 | |
| Seqirus USA INC | $13.54 | 2019 | |
| Assertio Therapeutics, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Brand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.